Search

Ceftobiprole

[L50467] It received its first approval in Canada in October 2017 for use in certain patients with bacterial pneumonia,[L50472] and was subsequently approved in the United States with additional indications … for skin and skin structure infections and bacteremia in April 2024.

Scarlet red

Scarlet red is under investigation in clinical trial NCT00591916 (New Treatment for Donor Sites).

Carglumic acid

Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. … This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and cause neurologic problems, cerebral edema, coma, and death.

Mexazolam

[A184910] The use of benzodiazepines in the treatment of anxiety is generally a second line measure.[A184910] … [A184910] Mexazolam's structure is similar to that of other benzodiazepines such as [oxazolam] and [cloxazolam].

Acenocoumarol

This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation. … Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase.

Aceclofenac

It is a more commonly prescribed drug in Europe. … In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical modification in effort to improve the gastrointestinal tolerability of the drug.

(+)-menthol

Naloxegol

It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. … Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca.

Ceftobiprole medocaril

[L50467] It received its first approval in Canada in October 2017 for use in certain patients with bacterial pneumonia,[L50472] and was subsequently approved in the United States with additional indications … for skin and skin structure infections and bacteremia in April 2024.

Dasiglucagon

[L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE. … Although it tends to be more common in type 1 diabetes mellitus, occurring in about 22% to 46% of patients annually, about 7% to 25% of patients with type 2 diabetes mellitus treated with insulin experience